Literature DB >> 8699324

Synthesis and antihypertensive activity of N-(alkyl/alkenyl/aryl)-N-heterocyclic ureas and thioureas.

O Vajragupta1, A Pathomsakul, C Matayatsuk, L Ruangreangyingyod, Y Wongkrajang, W O Foye.   

Abstract

A variety of N-(alkyl/alkenyl/aryl-N-heterocyclic ureas and thioureas were synthesized as potential antihypertensives. The selected heterocyclic nuclei were the 6-substituted quinoline and the pyridine. Eleven synthesized compounds and seven related compounds in the series were evaluated orally at a dose of 100 mg/kg in conscious deoxycorticosterone acetate/saline-treated hypertensive rats by the tail-cuff method. Seventeen out of the eighteen tested compounds possessed significant antihypertensive activity (p < 0.05). 1-n-Propyl-3-[2'-(6-methoxy)quinolyl]urea (9), showing 29.1% reduction in systolic blood pressure, was the most active compound in the series. Two other compounds producing a fall in systolic blood pressure of the same magnitude were 1-allyl-3-[2'-(6-methyl)quinolyl]thiourea (4) and 1-n-propyl-3-[(2'-pyridyl)methyl]urea (17). Compound 17 with rapid onset caused significant relaxation (p < 0.01) of isolated rabbit femoral artery and guinea pig atrium but had no effect on heart rate. However, none of these exhibited higher potency than prazosin (5 mg/kg). The potency, onset, and duration of action improved when the heterocyclic nucleus was pyridine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699324     DOI: 10.1021/js930295x

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Novel cardiac protective effects of urea: from shark to rat.

Authors:  X Wang; L Wu; M Aouffen; M A Mateescu; R Nadeau; R Wang
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  In vivo metabolism of N-phenyl-N'-(3,5-dimethylpyrazole-4-yl) thiourea in rats.

Authors:  Bedia Koçyiğit Kaymakcioğlu; Sevim Rollas; Feyza Kartal-Aricioğlu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Oct-Dec       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.